Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new online training tool being developed by the Genomics Education Programme for scientists processing tumour samples for whole genome sequencing will feature Dr Clare Verrill, a Senior Clinical Lecturer in Pathology at the Nuffield Department of Surgical Sciences.

Many of the first healthcare professionals to use the tool will be those processing tumour samples for Genomics England’s 100,000 Genomes Project, which aims to analyse whole genome sequences from thousands of patients to develop a greater understanding of the basis of disease. The insights gained from the project will have a huge impact on histopathology.

Whole genome sequencing can only be successfully performed on DNA from tumour samples with a suitable percentage of tumour tissue and the minimum required amount of DNA. This new training tool will consist of four educational modules and one assessment module covering tumour assessment for whole genome sequencing and introducing one reliable method of assessing tumour samples in 3D. It is anticipated that histopathologists, clinical and biomedical scientists working in NHS Genomic Medicine Centres will be the first to use the tool.  

Dr Verrill, who is the Lead for Molecular Pathology at the Oxford Genomic Medicine Centre, provides an introduction to the modules and the assessment model, explaining why there is a need for standardised training. Dr Verrill said: ‘Ultimately, the goal of this training tool is to help us deliver a better service to patients. If we can assess a tumour for genomic sequencing accurately and efficiently, we will ensure that as many eligible samples as possible are selected for DNA extraction and sequencing with minimal delay or errors.

‘And of course, the goal beyond that is that, in time, we will gain a much deeper understanding of cancer at a molecular level, to better inform our patients’ diagnosis, treatment and prognostic information.’

The tool will be launched by the Genomics Education Programme in spring 2017.

Read more about the 100,000 Genomes Project.

Similar stories

New Cochrane evidence explores treatment options for chronic ear disease

Publication Research

A new Evidently Cochrane blog post for World Hearing Day summarises seven recent reviews on medical treatments for infection and inflammation of the middle ear.

New reporting guidelines to bridge the gap from development to implementation in clinical artificial intelligence

Innovation Research

In a correspondence to Nature Medicine, a team of Oxford-led academics describe upcoming new guidelines to improve the reporting of early clinical stage (or first-with-human) evaluation of decision support systems driven by artificial intelligence.

Cochrane ENT awarded NIHR funding for COVID-19 project

Awards and appointments Coronavirus COVID-19 Research

Cochrane ENT at the Nuffield Department of Surgical Sciences has been awarded funding by the National Institute for Health Research (NIHR) to complete a suite of living systematic reviews investigating the effectiveness and safety of interventions to prevent and treat loss of smell after COVID-19 infection.

First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy

Coronavirus COVID-19 Publication Research

Today University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.

Applications for Oxford-Wolfson-Marriott-Patel Scholarship now open

Awards and appointments Department Research

The Nuffield Department of Surgical Sciences (NDS) are pleased to confirm that one scholarship will be available for Home (UK) and Republic of Ireland (ROI) candidates for the DPhil in Surgical Sciences, starting in Michaelmas Term 2021.

Oxford University breakthrough on global COVID-19 vaccine

Coronavirus COVID-19 Research

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.